CA Patent

CA2399169A1 — Diagnostic methods for determining susceptibility to convulsive conditions

Assigned to Queens University at Kingston · Expires 2003-03-07 · 23y expired

What this patent protects

The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially .beta.-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical an…

USPTO Abstract

The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially .beta.-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liquid chromatography system, for use in the invention are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA2399169A1
Jurisdiction
CA
Classification
—
Expires
2003-03-07
Drug substance claim
No
Drug product claim
No
Assignee
Queens University at Kingston
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.